Strontium Treatment Potentiates Bone Anabolic Action of Intermittent PTH in Ovariectomized Rats

Area of Science:

• Biomedical Sciences
• Bone Biology
• Pharmacology

Background:

• Osteoporosis is a significant health concern characterized by bone fragility.
• Teriparatide (PTH1-34) is an anabolic agent for osteoporosis treatment.
• Strontium (Sr) has shown potential in modulating bone metabolism.

Purpose of the Study:

• To investigate the synergistic effects of combining strontium (Sr) with teriparatide (PTH1-34) on bone anabolism in an ovariectomized rat model.
• To determine if Sr can potentiate the bone anabolic action of intermittent PTH1-34.

Main Methods:

• Ovariectomized (Ovx) rats were treated with vehicle, Sr alone, PTH1-34 alone, or a combination of Sr and PTH1-34 for 8 weeks.
• Bone microarchitecture, volumetric bone mineral density (vBMD), and mechanical strength were assessed.
• Osteoblast cultures were used to evaluate gene expression related to bone formation and resorption.

Main Results:

• PTH1-34 improved trabecular microarchitecture and strength, while Sr alone increased tissue-level vBMD.
• Co-treatment with Sr and PTH1-34 significantly enhanced trabecular thickness, vBMD, bone material properties, and strength compared to PTH1-34 alone.
• Combined therapy also improved cortical bone thickness and strength, and modulated osteogenic gene expression (Igf1, Alpl) and resorption markers (Rankl, Opg).

Conclusions:

• Combining Sr with PTH1-34 provides synergistic benefits for bone anabolism.
• This integrated approach enhances bone mass, quality, and mechanical strength, offering a superior therapeutic strategy for osteoporosis.